Corvus Pharmaceuticals, Inc. (CRVS) Reports In-Line Q2 EPS

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q2 EPS of ($0.14), in-line with the analyst estimate of ($0.14).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Waller: Recent Increases In Core Inflation Are Quite Broad
• Knight Transportation (KNX) PT Raised to $85 at Stifel Ahead of Q2 Earnings